Kibow Therapeutics is a clinical-stage developer of live biotherapeutics for persons with chronic kidney disease (CKD). The Company is advancing potential first-in-class therapies to selectively modulate the gut microbiome to improve kidney function and quality of life. Kibow Therapeutics is focused first on KT-301, an encapsulated consortium of proprietary strains of commensal bacteria targeting uremic toxins associated with CKD. Phase 2 clinical studies in CKD patients are underway to assess KT-301’s safety and its ability to halt or slow progression of CKD. A Phase 2 study in end-stage renal disease (ESRD) patients undergoing dialysis is also planned. Kibow Biotech is a wholly owned subsidiary of Kibow Therapeutics. For more than 20 years Kibow Biotech has built a leadership position in probiotic research and development, with a number of commercialized products, led by Renadyl™ for the maintenance of renal health. Kibow Therapeutics is headquartered in Newtown Square, PA.
Dedicated to Helping Patients with Chronic Kidney Disease
We are advancing potential first-in-class live biotherapeutics for CKD and ESRD.
Kibow Biotech, a wholly owned subsidiary of Kibow Therapeutics, is a leader in probiotic research and development with commercialized products including Renadyl™.
Now in its 25th year, Kibow Biotech is a leading source of scientifically formulated probiotic/prebiotic dietary supplements. Guided by its visionary founder, Natarajan Ranganathan, Ph.D., and a group of internationally recognized scientific advisors, Kibow Biotech has accomplished pharmaceutical-like development and validation for its proprietary probiotic/prebiotic formulations for kidney health and general wellness purposes. Kibow Biotech has been awarded highly competitive Small Business Innovation Research (SBIR) Grant Awards from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK-NIH) and Qualifying Therapeutic Discovery Project (QTDP) Programs. Additionally, Kibow Biotech has secured USAID grant funding for R&D and product development.
Kibow Biotech is a leader provider of probiotic dietary supplements for kidney health, marketed under the brand names Renadyl™ and Azodyl® (for veterinary use).
Our leadership team includes creative, resourceful, and well-connected life sciences industry veterans. In addition, we bring 25 years of operating experience as a developer of live biotherapeutics across multiple domains, with a focus on kidney health.
We Strive to Improve Outcomes with Our Novel Adjunctive CKD Therapies
Chronic kidney disease (CKD) is characterized by a gradual loss of kidney function. As many as one in nine U.S. adults has CKD. Kibow Therapeutics is advancing novel, non-invasive therapies to improve quality of life and slow the progression of CKD.